| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P Camps, B Cusack, W D Mallender, R E El Achab, J Morral, D Muñoz-Torrero, T L Rosenberr. Huprine X is a novel high-affinity inhibitor of acetylcholinesterase that is of interest for treatment of Alzheimer's disease. Molecular pharmacology. vol 57. issue 2. 2000-03-02. PMID:10648652. |
inhibitors of the enzyme acetylcholinesterase (ache) slow and sometimes reverse the cognitive decline experienced by individuals with alzheimer's disease. |
2000-03-02 |
2023-08-12 |
human |
| Y Li, L Liu, J Kang, J G Sheng, S W Barger, R E Mrak, W S Griffi. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 20. issue 1. 2000-01-27. PMID:10627591. |
cholinergic dysfunction in alzheimer's disease has been attributed to stress-induced increases in acetylcholinesterase (ache) activity. |
2000-01-27 |
2023-08-12 |
rat |
| Y Li, L Liu, J Kang, J G Sheng, S W Barger, R E Mrak, W S Griffi. Neuronal-glial interactions mediated by interleukin-1 enhance neuronal acetylcholinesterase activity and mRNA expression. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 20. issue 1. 2000-01-27. PMID:10627591. |
neuronal stress in alzheimer's disease may induce increases in ache expression and activity through a molecular cascade that is mediated by sapp-induced microglial activation and consequent overexpression of il-1. |
2000-01-27 |
2023-08-12 |
rat |
| M P Marzolo, R von Bernhardi, N C Inestros. Mannose receptor is present in a functional state in rat microglial cells. Journal of neuroscience research. vol 58. issue 3. 1999-11-23. PMID:10518112. |
because there is evidence suggesting that manr could mediate some of the nonenzymatic effects of acetilcholinesterase (ache) and the enzyme seems to be involved in alzheimer's disease (ad), we looked for manr in microglia, evaluating the functionality of the receptor. |
1999-11-23 |
2023-08-12 |
human |
| T Kosasa, Y Kuriya, K Matsui, Y Yamanish. Effect of donepezil hydrochloride (E2020) on basal concentration of extracellular acetylcholine in the hippocampus of rats. European journal of pharmacology. vol 380. issue 2-3. 1999-11-01. PMID:10513568. |
the effects of oral administration of the centrally acting acetylcholinesterase (ache) inhibitors, donepezil hydrochloride (donepezil: e2020: (+/-)-2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxy-indan-1-one monohydrochloride), tacrine (9-amino-1,2,3,4-tetrahydroacridine hydrochloride) and ena-713 (rivastigmine: (s)-n-ethyl-3-[(1-dimethyl-amino)ethyl]-n-methyl-phenylcarbamate hydrogentartrate), which have been developed for the treatment of alzheimer's disease, on the extracellular acetylcholine concentration in the hippocampus of rats were evaluated by using a microdialysis technique without adding cholinesterase inhibitor to the perfusion solution. |
1999-11-01 |
2023-08-12 |
rat |
| F J Muñoz, N C Inestros. Neurotoxicity of acetylcholinesterase amyloid beta-peptide aggregates is dependent on the type of Abeta peptide and the AChE concentration present in the complexes. FEBS letters. vol 450. issue 3. 1999-07-22. PMID:10359075. |
our results show that ache-abeta1-40 aggregates are more toxic than those of ache-abeta1-42 and that the neurotoxicity depends on the amount of ache bound to the complexes, suggesting that ache may play a key role in the neurodegeneration observed in alzheimer brain. |
1999-07-22 |
2023-08-12 |
rat |
| C Y Li, H Wang, H Xue, P R Carlier, K M Hui, Y P Pang, Z W Li, Y F Ha. Bis(7)-tacrine, a novel dimeric AChE inhibitor, is a potent GABA(A) receptor antagonist. Neuroreport. vol 10. issue 4. 1999-06-29. PMID:10208550. |
heptylene-linked bis-(9-amino-1,2,3,4-tetrahydroacridine) (bis(7)-tacrine) is a potential palliative therapeutic agent for alzheimer's disease (ad), on the basis of its superior acetylcholinesterase (ache) inhibition and memory-enhancing potency relative to tacrine. |
1999-06-29 |
2023-08-12 |
rat |
| D E Moss, P Berlanga, M M Hagan, H Sandoval, C Ishid. Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alzheimer disease and associated disorders. vol 13. issue 1. 1999-05-25. PMID:10192638. |
the purpose of the present study was to evaluate methanesulfonyl fluoride (msf), a very long-acting cns-selective acetylcholinesterase (ache) inhibitor, as a palliative treatment for senile dementia of the alzheimer type (sdat). |
1999-05-25 |
2023-08-12 |
human |
| D E Moss, P Berlanga, M M Hagan, H Sandoval, C Ishid. Methanesulfonyl fluoride (MSF): a double-blind, placebo-controlled study of safety and efficacy in the treatment of senile dementia of the Alzheimer type. Alzheimer disease and associated disorders. vol 13. issue 1. 1999-05-25. PMID:10192638. |
msf produced a mean of 89.5% inhibition of erythrocyte ache in patients and improved cognitive performance as measured by the mmse, alzheimer disease assessment scale-cognitive subscale (adas-cog), global deterioration scale, and the clinical interview based impression of change (cibic). |
1999-05-25 |
2023-08-12 |
human |
| J Sáez-Valero, G Sberna, C A McLean, D H Smal. Molecular isoform distribution and glycosylation of acetylcholinesterase are altered in brain and cerebrospinal fluid of patients with Alzheimer's disease. Journal of neurochemistry. vol 72. issue 4. 1999-04-13. PMID:10098867. |
ache from alzheimer's disease (ad) patients was found to bind differently to two lectins, concanavalin a and wheat germ agglutinin, than ache from controls. |
1999-04-13 |
2023-08-12 |
Not clear |
| F Giubilei, S Strano, B P Imbimbo, P Tisei, G Calcagnini, S Lino, M Frontoni, M Santini, C Fiesch. Cardiac autonomic dysfunction in patients with Alzheimer disease: possible pathogenetic mechanisms. Alzheimer disease and associated disorders. vol 12. issue 4. 1999-03-18. PMID:9876965. |
we studied a possible correlation between autonomic cardiac activity and the level of the red blood cell acetylcholinesterase (ache) in patients with probable alzheimer disease (ad). |
1999-03-18 |
2023-08-12 |
Not clear |
| S L Rogers, L T Friedhof. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following single oral doses. British journal of clinical pharmacology. vol 46 Suppl 1. 1999-01-28. PMID:9839758. |
the aim of this study was to characterize the pharmacokinetic and pharmacodynamic profile of donepezil hcl, a chemically distinct and specific acetylcholinesterase (ache) inhibitor for the treatment of alzheimer's disease, following administration of single oral doses. |
1999-01-28 |
2023-08-12 |
Not clear |
| S L Rogers, N M Cooper, R Sukovaty, J E Pederson, J N Lee, L T Friedhof. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. British journal of clinical pharmacology. vol 46 Suppl 1. 1999-01-28. PMID:9839759. |
the aim of this study was to characterize the pharmacokinetics and pharmacodynamics of donepezil hcl, a new, chemically distinct and specific acetylcholinesterase (ache) inhibitor for the treatment of alzheimer's disease, following multiple-dose administration. |
1999-01-28 |
2023-08-12 |
Not clear |
| A B Bonnefont, F J Muñoz, N C Inestros. Estrogen protects neuronal cells from the cytotoxicity induced by acetylcholinesterase-amyloid complexes. FEBS letters. vol 441. issue 2. 1999-01-22. PMID:9883888. |
the senile plaques present in alzheimer's disease (ad) are composed of a core of amyloid beta-peptide (abeta) plus several proteins including acetylcholinesterase (ache). |
1999-01-22 |
2023-08-12 |
mouse |
| S L Roger. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil. Dementia and geriatric cognitive disorders. vol 9 Suppl 3. 1999-01-21. PMID:9853200. |
donepezil hci is a piperidine-based reversible acetylcholinesterase (ache) inhibitor, chemically distinct from other cholinesterase (che) inhibitors and rationally designed to treat the symptoms of alzheimer's disease (ad). |
1999-01-21 |
2023-08-12 |
human |
| R M Nitsch, S Rossner, C Albrecht, M Mayhaus, J Enderich, R Schliebs, M Wegner, T Arendt, H von der Kamme. Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter. Journal of physiology, Paris. vol 92. issue 3-4. 1999-01-13. PMID:9789819. |
this possibility suggests testing of cholinomimetic compounds currently in development for the treatment of alzheimer's disease for their potential ability to increase ache gene expression. |
1999-01-13 |
2023-08-12 |
human |
| V Jelic, T Dierks, K Amberla, O Almkvist, B Winblad, A Nordber. Longitudinal changes in quantitative EEG during long-term tacrine treatment of patients with Alzheimer's disease. Neuroscience letters. vol 254. issue 2. 1999-01-08. PMID:9779926. |
quantitative eeg is a potentially useful tool in demonstrating the effects of treatments with acetylcholinesterase (ache) inhibitors on the progression of alzheimer's disease (ad). |
1999-01-08 |
2023-08-12 |
Not clear |
| N C Inestrosa, R Alarcó. Molecular interactions of acetylcholinesterase with senile plaques. Journal of physiology, Paris. vol 92. issue 5-6. 1999-01-08. PMID:9789834. |
acetylcholinesterase (ache) present in alzheimer plaques is resistant to low ph, anti-che inhibitors and high substrate concentrations in comparison with the free enzyme. |
1999-01-08 |
2023-08-12 |
Not clear |
| R D Moreno, F O Campos, F Dajas, N C Inestros. Developmental regulation of mouse brain monomeric acetylcholinesterase. International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience. vol 16. issue 2. 1998-12-09. PMID:9762585. |
results are discussed in terms of the biological significance of the embryonic g1 form, and its resemblance to the ache activity found, associated with the senile plaques present in the brains of alzheimer's patients. |
1998-12-09 |
2023-08-12 |
mouse |
| R J Polinsk. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Clinical therapeutics. vol 20. issue 4. 1998-11-18. PMID:9737824. |
moreover, rivastigmine preferentially inhibits the g1 enzymatic form of ache, which predominates in the brains of patients with alzheimer's disease (ad). |
1998-11-18 |
2023-08-12 |
human |